{"disease":{"id":"malignant-hypertension","name":"Malignant hypertension","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"mecamylamine","indication_name":"Uncomplicated malignant hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inversine","generic_name":"MECAMYLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor; alpha3/beta2","drug_class":"Autonomic Ganglionic Blocker","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"mecamylamine-hydrochloride","indication_name":"Uncomplicated malignant hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MECAMYLAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"fenoldopam","indication_name":"Malignant essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corlopam","generic_name":"FENOLDOPAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(1A) dopamine receptor","drug_class":"Dopaminergic Agonist","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"benzylhydrochlorothiazide","indication_name":"Malignant hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Behyd","generic_name":"benzylhydrochlorothiazide","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Behyd works by blocking sodium reabsorption in the kidneys, which increases urine production and reduces blood pressure."},{"drug_id":"nitroprusside","indication_name":"Malignant essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sodium Nitroprusside","generic_name":"NITROPRUSSIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Vasodilator","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03755726","title":"A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier de PAU","has_results":false},{"nct_id":"NCT06629363","title":"Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier de PAU","has_results":false},{"nct_id":"NCT06939114","title":"Optic Nerve Sonography to Monitor Intracranial Pressure After Ischemic sTrokE - The ONSITE Study","phase":"","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT04991077","title":"Interrupters of VAscular daMAge in Malignant Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Centre Hospitalier de PAU","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}